Fosun International Ltd Has $3.35 Million Stake in XOMA Corp (XOMA)
Fosun International Ltd lessened its position in XOMA Corp (NASDAQ:XOMA) by 14.7% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 269,877 shares of the biotechnology company’s stock after selling 46,357 shares during the period. Fosun International Ltd’s holdings in XOMA were worth $3,346,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently modified their holdings of XOMA. Smart Portfolios LLC bought a new position in shares of XOMA in the first quarter worth approximately $36,000. California Public Employees Retirement System lifted its position in XOMA by 11.5% during the fourth quarter. California Public Employees Retirement System now owns 11,860 shares of the biotechnology company’s stock valued at $150,000 after purchasing an additional 1,220 shares during the period. First Manhattan Co. lifted its position in XOMA by 100.0% during the first quarter. First Manhattan Co. now owns 20,000 shares of the biotechnology company’s stock valued at $247,000 after purchasing an additional 10,000 shares during the period. Two Sigma Advisers LP lifted its position in XOMA by 9.9% during the fourth quarter. Two Sigma Advisers LP now owns 32,195 shares of the biotechnology company’s stock valued at $407,000 after purchasing an additional 2,905 shares during the period. Finally, Chicago Equity Partners LLC bought a new position in XOMA during the fourth quarter valued at approximately $501,000. Hedge funds and other institutional investors own 48.52% of the company’s stock.
XOMA stock traded down $0.18 during midday trading on Wednesday, reaching $17.34. 11,107 shares of the company traded hands, compared to its average volume of 67,811. The company has a market cap of $153.60 million, a price-to-earnings ratio of -10.91 and a beta of 2.38. XOMA Corp has a 12 month low of $11.02 and a 12 month high of $25.99. The company has a quick ratio of 7.20, a current ratio of 7.20 and a debt-to-equity ratio of 1.13.
In other XOMA news, insider Value Fund L. P. Biotechnology purchased 27,913 shares of the firm’s stock in a transaction on Tuesday, May 14th. The shares were acquired at an average cost of $14.63 per share, for a total transaction of $408,367.19. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Bvf Partners L. P/Il purchased 3,797 shares of the firm’s stock in a transaction on Monday, May 13th. The stock was acquired at an average price of $14.36 per share, for a total transaction of $54,524.92. The disclosure for this purchase can be found here. Insiders acquired 42,010 shares of company stock worth $612,963 over the last quarter. Insiders own 9.89% of the company’s stock.
A number of research analysts recently weighed in on XOMA shares. ValuEngine downgraded shares of XOMA from a “hold” rating to a “sell” rating in a research report on Wednesday, May 1st. HC Wainwright set a $30.00 price objective on shares of XOMA and gave the company a “buy” rating in a research report on Friday, April 12th. Wedbush set a $25.00 price objective on shares of XOMA and gave the company a “buy” rating in a research report on Tuesday, May 14th. Finally, Zacks Investment Research upgraded shares of XOMA from a “sell” rating to a “hold” rating in a research report on Saturday, March 9th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. XOMA currently has a consensus rating of “Hold” and a consensus target price of $23.75.
XOMA Company Profile
XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy.
Recommended Story: Asset Allocation Models, Which is Right For You?
Want to see what other hedge funds are holding XOMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for XOMA Corp (NASDAQ:XOMA).
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.